Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rafael Holdings, Inc. (RFL : NYSE)

• Company Description    Rafael Holdings Inc. manufactures metabolic oncology drugs to treat cancer. The company's product pipeline consists of CPI-613, CPI-618, CPI-1826 and CPI-3220 which are in clinical stages. Rafael Holdings Inc. is based in Newark, United States. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $2.13 Daily Weekly Monthly 20 Day Moving Average: 241,691 shares Shares Outstanding: 52.00 (millions) Market Capitalization: $110.76 (millions) Beta: 0.29 52 Week High: $3.96 52 Week Low: $1.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.40% -21.98% 12 Week 67.72% 63.12% Year To Date 80.51% 63.66%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 520 BROAD STREET - NEWARK,NJ 07102 USA ph: 212-658-1450 fax: - invest@rafaelholdings.com http://www.rafaelholdings.com

• General Corporate Information    Officers Howard Jonas - Chief Executive Officer Joshua Fine - Chief Operating Officer David Polinsky - Chief Financial Officer Alan Grayson - Director Markus W. Sieger - Director Peer Information Rafael Holdings, Inc. (GSAC) Rafael Holdings, Inc. (CASIF) Rafael Holdings, Inc. (ALCD.) Rafael Holdings, Inc. (OMNN) Rafael Holdings, Inc. (CGPI.) Rafael Holdings, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 75062E106 SIC: 2834 Fiscal Year Fiscal Year End: July Last Reported Quarter: 04/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 52.00 Most Recent Split Date: (:1) Beta: 0.29 Market Capitalization: $110.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.37 Price/Cash Flow: - Price / Sales: 113.02 EPS Growth vs. Year Ago Period: 21.05% vs. Previous Quarter: -15.38% Sales Growth vs. Year Ago Period: -50.55% vs. Previous Quarter: -15.17% ROE 04/30/26 - -41.27 01/31/26 - -37.27 10/31/25 - -32.82 ROA 04/30/26 - -35.32 01/31/26 - -31.02 10/31/25 - -27.55 Current Ratio 04/30/26 - 3.16 01/31/26 - 3.44 10/31/25 - 4.00 Quick Ratio 04/30/26 - 3.14 01/31/26 - 3.41 10/31/25 - 3.98 Operating Margin 04/30/26 - -3,701.63 01/31/26 - -2,846.60 10/31/25 - -2,748.30 Net Margin 04/30/26 - -3,321.74 01/31/26 - -2,846.60 10/31/25 - -3,044.70 Pre-Tax Margin 04/30/26 - -3,182.25 01/31/26 - -2,988.48 10/31/25 - -3,283.19 Book Value 04/30/26 - 1.55 01/31/26 - 1.60 10/31/25 - 1.72 Inventory Turnover 04/30/26 - 0.17 01/31/26 - 0.29 10/31/25 - 0.50 Debt-to-Equity 04/30/26 - 0.00 01/31/26 - 0.00 10/31/25 - 0.00 Debt-to-Capital 04/30/26 - 0.00 01/31/26 - 0.06 10/31/25 - 0.06

Powered by Zacks Investment Research ©